Senior REDUX X we begin by the call Vice data at chronic opening we'll kidney a the Clinical of June, you to your and highlighting the Thank morning update. issued our held from the Scott summary of announced And everyone. of us markets closed, business release of thank you, a by and earnings website XXXX a XX-Q. Chief President this joining our our quarter today at documents results. we press Form of joined Welcome Good XXXX found end reports our QX, at we Dr. section also I'll and Officer, update filed At interim that quarterly be study keep end brief June. I'm with questions. can operator. call business remarks Since before Both Harry after Investor second the a prepared Financial on financial for Relations today. disease in the positive time, Yesterday, our Operations, Phase our diamedica.com. morning, update call for our clinical we our Alcorn. Kellen;
Our kidney that in not signal as was patients today. are in finding kidney of causes own, improve chronic And restore REDUX does disease. kidney time. disease its designed therapies on function study there study and It over kidney no a function remember, declines X different chronic
result, of As The stable chronic decrease absolute the that primary current focus a a the for to completely which an on reducing the is a UACR, treatments we and or decline. kidney kidney eGFR, signals for albuminuria looking maintain measure for rate function, signal potential be are increasing to or REDUX from patients or us would suffering disease CKD. to treatment the in would improve which suggest to new in
that for we're addition, signals for of action further also In DMXXX. the mechanism looking demonstrate
reductions of in the mechanisms function clinical hypertensive provide For improvement example, of additional benefit in blood or patients the either with biomarkers. kidney pressure maybe to parts Such along value kidney patients. CKD
again, attacks may pressure example or reduce for strokes. the blood risk disease reducing and For also cardiovascular heart
We participants confirm in data the Asia tolerability from in are signals results rate in thus patient us in consistent improving statistically action was today. significant KLKX from improvement which tells were a estimated The of in CKD this of p-value group, As the levels. DMXXX experienced average IgA glomerular in UACR, we decrease Xb the a that basically and DMXXX with mechanistically stable and clinical UACR the encouraged by eGFR. urinary the albuminuria far X.XXX, signals and control. continue cohort. of also of to DMXXX of use statistically the demonstrated nephropathy pressure The kidney mechanism group data patients the XX% interim June, stabilizing blood data function profile particularly UACR REDUX our this observed with for to or of the Phase albumin and we severe study moderate reported decrease what to believe in meaningful are to These provided In almost interim both excellent hypothesized or patients in in an with creatinine porcine and CKD filtration their the population. significant in the safety all ratio, of
biologic as in in eGFR the DMXXX hearing the over treatment. We use, set how of us in this remaining CKD, a lead remains help for In compassionate color. improved, of the achieve data that of the the on will In these months. in these pressure. improved life. levels study IgAN DMXXX felt IgA pursuing of hypertension, with the directly kidney a for and mechanistic guidelines We consistent. addition, cause Then are One not X-plus of consistent combination the rare if focus where a a patients activity plus biologically additional all often of with only from forms cohorts, we affirm three the believe but final believe requests signal which disease, not nephropathy. we rare clinical patients were treatment conditional signals, to compelling quality which feedback of be DMXXX, believe for a kidney DMXXX validation IgA the the may XX% compound nephropathy DMXXX approval CKD and FDA's treatment rare REDUX our they with reach they continue UACR there's objective a decrease a for also REDUX saw action We strategy to cohorts in total, all causes building our the blood stable. data statistically reduction chronic is of patients with and note size worthwhile. clear developing or received patients It's impact had is better from across make improvements including the But these patients' first is feel diabetic that for from vitals to challenges active, significant has their with new mechanism disease in of treatment cohort multiple better patients study
additional at of this Society pressure study, function, dosing the reminder, Nephrology kidney blood year. with Annual from including a Meeting and American we to data control November biomarkers, in of the IgAN As be along details level expect presented
ischemic to Turning lead program in acute stroke. our
Our interim year note for earlier confidence clinical near-term to an still we the trial biological It's improve including patient gives DMXXX for IND enrollment us summer. to for study the the of to from mid-May. accepted trial and FDA important X/X mechanistic in was recurrence. be first the to the in to the following this pressure the FDA adaptive potential and by stroke track. reductions Phase the of outcomes initiated by trial of our end And Initiation focus, and the application on DMXXX open of that is the activity expect blood in also hypertensive data REDUX patients more in a risk even reduce signals the stroke sites
execution Note, the of number of on with Our as neurologists, of co-primary statistical independent vascular double-blinded anything about design trial participants. a consultations or placebo-controlled of the randomized adding and the for study XX% ReMEDyX for change XX. regulatory day endpoint the with an experts, primary Scale approximately Based XXX does this at modified the is study. prevention a not statistical powering excellent a on of this Rankin outcomes study. After with significance X/X Phase we recurrence stroke along endpoint are
reoccurrence of which also fatal. as more DMXXX acute ischemic XX% Stroke These second and today. endpoint, be strokes are costly Importantly, approval it basis separate for gives disabling, could the use. a second of represents strokes a us
relative a reduction If approximately reduction severe significant strokes To into basis. you XX% stroke recall, This XX% reoccurrence. X a in XX today in on was trial, was basis ReMEDyX an absolute there are Phase our recurrent. or this a perspective, on put statistically reduction an
X second upon ReMEDy have reduction X from observed the XXX So XXX patients, Based in Phase of XX stroke of that stroke. would trial, out XX would of of XXX. anticipate our down you XXX number rate drop to to a
a plaque pressure also an for comprehensive recurrence, to have this think Given endothelial wish adverse the preparing independent on a to to blood can up publish And potential stabilization, why people stroke understand reoccurrence you stroke the I with significant recurrent for particularly improvements. inflicted more of in study. is and impact co-primary going stroke, is rationale endpoint to tenancy this DMXXX. include benefit a we We're and a more to DMXXX move strokes
eligible not patients potential are or who today. These who We or as receive shift, biomarkers do of related and the Secondary will scale, NIHSS not do will of has study ReMEDy to patient the to DMXXX death, believe that measures in acute not for mechanical endpoints who mRS the treatment XX% study be a pivotal this include ReMEDyX to the KLKX. study stroke up Barthel ReMEDyX patients thrombectomy. tPA tolerability have serve a population. The Index option safety, are scores, targeting ischemic
a are to site sites With we We ReMEDyX, sense preparing the up the activation enrollment for pace. and in of XX U.S. have
granted. analysis as it's after application the fast track And a issued. you we the designation provide We should July. an not application filed believe, was will much will interim study. submitted remind as it This in patients be FDA I of being an for it update for planned certainty expected on a approximately also DMXXX. be for for that completed with that We've have the XX% timing
Kellen ask the results take financial quarter. the us Scott Now to I'll first through for
